Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.414
-0.018 (-4.12%)
At close: Mar 6, 2026, 4:00 PM EST
0.420
+0.006 (1.45%)
After-hours: Mar 6, 2026, 7:49 PM EST
Outlook Therapeutics Stock Forecast
OTLK's stock price has decreased by -72.4% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Outlook Therapeutics stock have an average target of 3.83, with a low estimate of 0.50 and a high estimate of 10. The average target predicts an increase of 825.12% from the current stock price of 0.41.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $0.5 | Hold | Reiterates | $0.5 | +20.77% | Feb 18, 2026 |
| Chardan Capital | Chardan Capital | Hold Maintains $1 | Hold | Maintains | $1 | +141.55% | Feb 18, 2026 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | +141.55% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $0.5 | Hold | Maintains | $1 → $0.5 | +20.77% | Jan 2, 2026 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $8 → $10 | Strong Buy | Maintains | $8 → $10 | +2,315.46% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
25.82M
from 1.41M
Increased by 1,726.70%
Revenue Next Year
46.57M
from 25.82M
Increased by 80.34%
EPS This Year
-0.63
from -1.79
EPS Next Year
-0.46
from -0.63
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 48.3M | 139.3M | |||
| Avg | 25.8M | 46.6M | |||
| Low | 13.7M | 8.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3,318.6% | 439.4% | |||
| Avg | 1,726.7% | 80.3% | |||
| Low | 870.6% | -67.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.29 | -0.22 | |||
| Avg | -0.63 | -0.46 | |||
| Low | -0.97 | -0.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.